CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Abstract Text:

The metabolic syndrome (MetS) confers an increased risk for diabetes and cardiovascular disease. Although high-sensitive C-reactive protein (hsCRP) concentrations are higher and adiponectin concentrations lower in MetS, there is no reliable biochemical measure that can capture its various features. We evaluated whether hsCRP, adiponectin, or the ratio of adiponectin or its oligomers, especially the high-molecular-weight (HMW) oligomer, to hsCRP predict MetS in 123 subjects with MetS compared with that in 91 healthy control subjects. MetS subjects had significantly higher hsCRP levels and lower total adiponectin and oligomer levels relative to control subjects (P < .0001). The HMW/total adiponectin and adiponectin/CRP ratios were significantly lower in MetS subjects than control subjects (P < .005). The odds ratio (OR) of MetS using the 75th percentile cutoff for CRP was 3.8 (95% confidence interval [CI], 2.1-6.8) and equivalent to low total adiponectin (OR, 2.5; 95% CI, 1.3-4.5), its oligomers, or the adiponectin/ hsCRP ratio (OR, 2.6; 95% CI, 1.5, 4.8). Thus, measurements of CRP, adiponectin, or its oligomers provide robust biomarkers for predicting MetS.

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of clinical pathology

VOLUME: 129

Page Numbers: 815-22

Journal Abbreviation: Am. J. Clin. Pathol.

ISSN: 0002-9173

DAY: 22

MONTH: May

YEAR: 2008

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370470

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.

AFFILIATION: Laboratory for Atherosclerosis and Metabolic Research, University of California, Davis, Medical Center, Sacramento, CA 95817, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: R01 HL74360

ACRONYM: HL

MEDLINETA: Am J Clin Pathol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers Related Publications

• A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.
• Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop.
• C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
• CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.
• Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis.
• Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.
• Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
• Editor's Perspective on Metabolic Syndrome for 2008.
• Editorial.
• Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.
• Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
• High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
• High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome.
• Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.
• Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State.
• Oxidative stress and atherosclerosis.
• RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
• Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
• Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
• Statins and biomarkers of inflammation.
• The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.
• The effect of weight loss and dietary fatty acids on inflammation.
• Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.